Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.71
At close: Apr 1, 7:56 PM EDT
$2.16
0.4526.32%
After Hours: Apr 1, 7:56 PM EDT
Comments
Loading...
Aptose Biosciences Inc COM NO PAR NEW Analyst Ratings and Price Targets | NASDAQ:APTO | Benzinga
Aptose Biosciences Inc COM NO PAR NEW Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Aptose Biosciences Inc COM NO PAR NEW Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Canaccord Genuity
Piper Sandler
RBC Capital
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for Aptose Biosciences Inc COM NO PAR NEW
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/28/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $2 → $6 | Maintains | Buy | Get Alert |
| 02/12/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 01/10/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 12/10/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 12/03/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $210 → $60 | Maintains | Buy | Get Alert |
| 06/14/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $210 → $210 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2024 | Buy Now | — | Canaccord Genuity | John Newman44% | $450 → $180 | Maintains | Buy | Get Alert |
| 04/03/2024 | Buy Now | — | Piper Sandler | Edward Tenthoff52% | $150 → $150 | Maintains | Overweight | Get Alert |
| 03/27/2024 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $690 → $690 | Maintains | Buy | Get Alert |
| 02/01/2024 | Buy Now | — | Piper Sandler | Edward Tenthoff52% | $360 → $150 | Maintains | Overweight | Get Alert |
| 11/10/2023 | Buy Now | — | RBC Capital | Gregory Renza46% | $690 → $540 | Maintains | Outperform | Get Alert |
| 09/07/2023 | Buy Now | — | Cantor Fitzgerald | Li Watsek40% | → $1140 | Reiterates | Overweight → Overweight | Get Alert |
| 08/11/2023 | Buy Now | — | Piper Sandler | Edward Tenthoff52% | $1110 → $360 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | — | RBC Capital | Gregory Renza46% | $1200 → $690 | Maintains | Outperform | Get Alert |
| 08/11/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $360 → $690 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | — | Oppenheimer | Matthew Biegler36% | $1500 → $450 | Maintains | Outperform | Get Alert |
| 06/12/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | $360 → $690 | Maintains | Buy | Get Alert |
| 06/12/2023 | Buy Now | — | Cantor Fitzgerald | Li Watsek40% | $180 → $1140 | Maintains | Overweight | Get Alert |
| 06/12/2023 | Buy Now | — | Oppenheimer | Matthew Biegler36% | $270 → $1500 | Maintains | Outperform | Get Alert |
| 06/07/2023 | Buy Now | — | Piper Sandler | Edward Tenthoff52% | $1350 → $1110 | Maintains | Overweight | Get Alert |
| 06/07/2023 | Buy Now | — | RBC Capital | Gregory Renza46% | $2250 → $1200 | Maintains | Outperform | Get Alert |
| 05/09/2023 | Buy Now | — | Oppenheimer | Matthew Biegler36% | → $4050 | Reiterates | → Outperform | Get Alert |
| 05/09/2023 | Buy Now | — | RBC Capital | Gregory Renza46% | → $2250 | Reiterates | → Outperform | Get Alert |
| 05/09/2023 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis45% | → $5400 | Reiterates | → Buy | Get Alert |
| 03/27/2023 | Buy Now | — | Canaccord Genuity | Carey Macrury43% | $5850 → $3600 | Maintains | Buy | Get Alert |
| 03/24/2023 | Buy Now | — | RBC Capital | Gregory Renza46% | → $2250 | Reiterates | → Outperform | Get Alert |
| 11/02/2022 | Buy Now | — | RBC Capital | Gregory Renza46% | $2700 → $2250 | Maintains | Outperform | Get Alert |
| 05/10/2022 | Buy Now | — | RBC Capital | Gregory Renza46% | $3150 → $2700 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Aptose Biosciences Inc COM NO PAR NEW (APTO) stock?
The latest price target for Aptose Biosciences Inc COM NO PAR NEW (NASDAQ:APTO) was reported by HC Wainwright & Co. on March 28, 2025. The analyst firm set a price target for $6.00 expecting APTO to rise to within 12 months (a possible 177.78% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aptose Biosciences Inc COM NO PAR NEW (APTO)?
The latest analyst rating for Aptose Biosciences Inc COM NO PAR NEW (NASDAQ:APTO) was provided by HC Wainwright & Co., and Aptose Biosciences Inc COM NO PAR NEW maintained their buy rating.
When was the last upgrade for Aptose Biosciences Inc COM NO PAR NEW (APTO)?
There is no last upgrade for Aptose Biosciences Inc COM NO PAR NEW
When was the last downgrade for Aptose Biosciences Inc COM NO PAR NEW (APTO)?
There is no last downgrade for Aptose Biosciences Inc COM NO PAR NEW.
When is the next analyst rating going to be posted or updated for Aptose Biosciences Inc COM NO PAR NEW (APTO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aptose Biosciences Inc COM NO PAR NEW, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aptose Biosciences Inc COM NO PAR NEW was filed on March 28, 2025 so you should expect the next rating to be made available sometime around March 28, 2026.
Is the Analyst Rating Aptose Biosciences Inc COM NO PAR NEW (APTO) correct?
While ratings are subjective and will change, the latest Aptose Biosciences Inc COM NO PAR NEW (APTO) rating was a maintained with a price target of $2.00 to $6.00. The current price Aptose Biosciences Inc COM NO PAR NEW (APTO) is trading at is $2.16, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.